SECOND AMENDMENT TO THE EXCLUSIVE LICENSE AGREEMENTExclusive License Agreement • October 20th, 2021 • Allarity Therapeutics, Inc. • Pharmaceutical preparations
Contract Type FiledOctober 20th, 2021 Company IndustryThis Second Amendment to the Exclusive License Agreement (“Second Amendment”) effective as of August 3, 2021 (“Second Amendment Effective Date”) is by and between: EISAI INC., with its principal office at 100 Tice Blvd., Woodcliff Lake, NJ 07093, United States of America (“Eisai”) and ALLARITY THERAPEUTICS A/S, with its principal office at Venlighedsvej 1, DK-2970 Hoersholm, Denmark (“Allarity”) (formerly known as Oncology Venture ApS), with reference to the following:
EXCLUSIVE LICENSE AGREEMENTExclusive License Agreement • October 20th, 2021 • Allarity Therapeutics, Inc. • Pharmaceutical preparations • New York
Contract Type FiledOctober 20th, 2021 Company Industry JurisdictionThis Exclusive License Agreement (this “Agreement”) is entered into as of July 6, 2017 (the “Effective Date”), between Oncology Venture, ApS, a company organized and existing under the laws of Denmark, whose principal place of business is located at Venlighedsvej 1, DK-2970 Hoersholm, Denmark (“OV”)
THIRD AMENDMENT TO EXCLUSIVE LICENSE AGREEMENTExclusive License Agreement • October 20th, 2021 • Allarity Therapeutics, Inc. • Pharmaceutical preparations
Contract Type FiledOctober 20th, 2021 Company IndustryThis Third Amendment (“Third Amendment”) to Exclusive License Agreement effective as of September 28, 2021 (“Third Amendment Effective Date”) is by and between: SMERUD MEDICAL RESEARCH INTERNATIONAL AS, a company organized and existing under the laws of Norway, with a principal place of business is located at Thunes vei 2, N-0274 Oslo, Norway (“Smerud”) and ALLARITY THERAPEUTICS A/S, a company organized and existing under the laws of Denmark, with a principal place of business at Venlighedsvej 1, DK-2970 Hoersholm, Denmark (“Allarity”)(formerly Oncology Venture A/S), with reference to the following: